Bleomycin lung injury in mice leads to an acute alveolitis followed by a fibroproliferative
response characterized by the accumulation of extracellular matrix. Because distinct regions …

Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis
using animal models, yet few of these compounds have replicated these beneficial effects in …

Fibroblast activation is transient in successful wound repair but persistent in fibrotic
pathologies. Understanding fibroblast deactivation during successful wound healing may …

Rationale: The model most often used to study the pathogenesis of pulmonary fibroses is the
bleomycin (BLM)-induced lung fibrosis model. Several treatments have been efficacious in …

Pulmonary fibrosis is a component of many interstitial lung diseases, including idiopathic
pulmonary fibrosis, a chronic, progressive disease for which there is currently no effective …

Different animal models of pulmonary fibrosis have been developed to investigate potential
therapies for idiopathic pulmonary fibrosis (IPF). The most common is the bleomycin model …

Idiopathic pulmonary fibrosis (IPF) is characterised by repeated injury to the alveolar
epithelium with loss of lung epithelial cells and abnormal tissue repair, resulting in excessive …

The bleomycin-induced rodent lung fibrosis model is commonly used to study mechanisms
of lung fibrosis and to test potential therapeutic interventions, despite the well recognized …

The pathogenesis of pulmonary fibrosis remains incompletely understood. Studies of
associated inflammation have led to the discovery of a number of cytokines and chemokines …

Interstitial lung fibrosis can develop as a consequence of occupational or medical exposure,
as a result of genetic defects, and after trauma or acute lung injury leading to …